<DOC>
	<DOCNO>NCT00664365</DOCNO>
	<brief_summary>This study first administration GSK958108 man . The study evaluate safety , tolerability pharmacokinetics single ascend dos GSK958108 evaluate effect food GSK958108 pharmacokinetics</brief_summary>
	<brief_title>FTIH Study With GSK958108</brief_title>
	<detailed_description />
	<mesh_term>Premature Ejaculation</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male 18 65 year age Male subject must agree use one contraception method per protocol . This criterion must follow time first dose study medication 3 month last dose . Body weight &gt; 50 kg ( 110 lb ) men BMI within range 19.0 29.9 kg/m2 inclusive ) Capable give write informed consent , include compliance requirement restriction list consent form . The subject visual acuity equivalent 20/20 eye , appropriate correction need The subject able cooperate part eye examination ( include dilation mydriatic ) The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine ( Can repeat screen ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen ( exception phase I hepatic impairment study , oncology study , hepatitis , hepatic fibrosis , HIV study ) . A positive test HIV antibody . History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . The subject prolactin , total free testosterone , LH , FSH outside normal range ( discussed Medical Monitor , necessary ) . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit average daily intake great 3 unit ( male ) . One unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity intolerance drug effect serotonin , include serotoninreuptake inhibitor ( SSRIs ) , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject history migraine . The subject history psychiatric illness . Any history suicidal attempt behaviour . The subject history eye disorder color blind , exclude myopia presbyopia . Unwillingness inability follow procedure outline protocol . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice [ and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ] 7 day prior first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Premature ejaculation .</keyword>
	<keyword>FTIH ,</keyword>
	<keyword>GSK958108 ,</keyword>
	<keyword>5HT1a antagonist ,</keyword>
</DOC>